Canada - Tiếng Anh - Health Canada

pharmascience inc - dihydroergotamine mesylate - liquid - 1mg - dihydroergotamine mesylate 1mg - sympatholytic (adrenergic blocking) agents

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

crealta pharmaceuticals llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 2 mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - ergotamine tartrate; caffeine - oral tablet - 1mg ; 100mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance pharmaceuticals ltd - ergotamine tartrate; caffeine - suppository - 2mg ; 100mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - ergotamine tartrate; caffeine - oral tablet - 1mg ; 100mg

Vương quốc Anh - Tiếng Anh - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (canada) - dihydroergotamine mesilate - solution for injection - 1mg/1ml

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

hikma farmaceutica - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) -

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - ergotamine tartrate 0.36mg - aerosol inhaler, metered dose - 0.36 mg/dose - active: ergotamine tartrate 0.36mg

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

it3 medical llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - dihydroergotamine mesylate - injection ampoule - 1mg/1ml - antimigraine preparations